Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aptinyx
Biotech
Molecular Templates halves head count as cash crunch looms
The Bristol Myers-partnered biotech is halving its 222-person team and stopping clinical development of a HER2 drug candidate.
Nick Paul Taylor
Mar 31, 2023 6:30am
Aptinyx dumps dementia drug, stops PTSD trial after phase 2 flop
Feb 28, 2023 6:15am
Drugs up for sale, on the shelf in biotech pipeline clear-outs
Nov 9, 2022 9:40am
Strike 3: Aptinyx's pain prospect flunks 3rd midphase trial
Aug 12, 2022 8:23am
Aptinyx pauses phase 2 trial of higher dose PTSD med
Apr 20, 2022 1:08pm
Aptinyx posts phase 2 PTSD win 2 years after diabetes pain flop
Oct 20, 2020 7:17am